Rekvina Laboratories share news, announcements and annual reports
BSE: 526075Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹55.79.
30 Oct: open ₹55.79, high ₹58.57, low ₹53.30
- Under BSE's graded surveillance, stage 0, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹61 Cr4,235th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −139.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,423
Rekvina Laboratories share news and announcements
399 announcements, routine notices left out, newest first. Page 4 of 8.
Feb 2024
2 Feb · Board meeting
Meeting on 12 Feb 2024: quarterly results
Nov 2023
9 Nov · Non-Applicability Of Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
3 Nov · Board meeting
Meeting on 9 Nov 2023: quarterly results
Oct 2023
Sep 2023
29 Sep · Announcement under Regulation 30 (LODR)-Meeting Updates
Aug 2023
4 Aug · Board meeting
Meeting on 11 Aug 2023: quarterly results
Jun 2023
8 Jun · Revised Financials Result
8 Jun · Board meeting
May 2023
30 May · Non-Applicability Of Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended On March 2023.
17 May · Board meeting
Meeting on 30 May 2023: audited results3 May · Board meeting
Meeting on 3 May 20233 May · Outcome Under Regulation 30 Of Securities Exchange And Board Of India (Listing Obligations And Disclosures Requirement) Regulations, 2015
Apr 2023
20 Apr · Compliance Certificate Under Reg. 7(3) Of SEBI (LODR) Regulations, 2015
14 Apr · Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended On 31.03.2023
Feb 2023
6 Feb · Board meeting
Meeting on 13 Feb 2023: quarterly results
Nov 2022
22 Nov · Non-Applicability Of Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
14 Nov · Board meeting
10 Nov · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 07 Nov · Board meeting
Meeting on 14 Nov 2022: quarterly results
May 2022
26 May · Board meeting
20 May · Board meeting
Meeting on 26 May 2022: audited results